

FURIO PACINI M.D.

Scientific publications (1977-2013)

220 peer reviewed articles published in international journals.

1. Pinchera A, Mariotti S, Vitti P, Tosi M, Grasso L, **Pacini F**, Buti R, Baschieri L: Interference of serum thyroglobulin in the radioassay for serum antithyroglobulin antibodies. *J. Clin. Endocrinol. Metab.* 45:1070, 1977.
2. **Pacini F**, Pinchera A, Giani C, Grasso L, Doveri F, Baschieri L: Serum thyroglobulin in thyroid carcinoma and other thyroid disorders. *J Endocrinol Invest* 3:283, 1980.
3. **Pacini F**, Pinchera A, Giani C, Baschieri L: Serum thyroglobulin concentrations and 131-I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). *Clin Endocrinol* 13:107, 1980.
4. **Pacini F**, Vitti P, Ambrosino N, Giani C, Baschieri L: Adriamycin chemotherapy of thyroid carcinoma. A study in 18 patients. *Chem Oncol* 5:54, 1981.
5. **Pacini F**, Fragù P, Mariotti S, De Groot LJ: Effect of indomethacin on phytohemagglutination-stimulated peripheral blood lymphocytes in thyroid autoimmune diseases. *J Clin Immunol* 2:335, 1982.
6. Sridama V, **Pacini F**, De Groot LJ: Decreased suppressor T-lymphocytes in autoimmune thyroid diseases detected by monoclonal antibodies. *J Clin Endocrinol Metab* 54:316, 1982.
7. **Pacini F**, Sridama V, Refetoff S: Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. *J Endocrinol Invest* 5:403, 1982.
8. Sridama V, **Pacini F**, Yang SL, Moawad A, Reilly M, De Groot LJ: Decreased levels of helper T cells. A possible cause of immunodeficiency in pregnancy. *N Engl J Med* 307:352, 1982.
9. **Pacini F** and DeGroot LJ: Studies of immunoglobulin synthesis in cultures of peripheral T and B lymphocytes: reduced T-suppressor cell activity in Graves' disease. *Clin Endocrinol (Oxf)* 18:219, 1983.

10. **Pacini F**, Nakamura H and DeGroot LJ: Effect of hypo- and hyperthyroidism on the balance between helper and suppressor T cells in rats. *Acta Endocrinol* 103:528, 1983.
11. **Pacini F**, Sridama V, Pressendo J, DeGroot LJ and Medof ME: Binding of immunoglobulin-G from patients with thyroid autoimmune disease to normal T lymphocytes. *Clin Endocrinol (Oxf)* 18:29, 1983.
12. **Pacini F**, Lari R, LaRicca P, Grasso L, DiBartolo F, Fenzi GF, Ciampi M, Gragnani SG, Baschieri L and Pinchera A: Serum thyroglobulin determination in the differential diagnosis of congenital hypothyroidism. *J Endocrinol Invest* 7:29, 1984.
13. Martino E, Bambini G, Aghini-Lombardi F, Motz E, **Pacini F**, Lari R, Baschieri L and Pinchera A: Serum tissue polypeptide antigen (TPA) in thyroid cancer. *J Endocrinol Invest* 7:249, 1984.
14. **Pacini F**, Lari R, LaRicca P, Grasso L, Taddei D, Bardini N, Fenzi GF, DiBartolo F, Baschieri L and Pinchera A: Serum thyroglobulin in newborns' cord blood, in childhood and adolescence: a physiological indicator of thyroidal status. *J Endocrinol Invest* 7:445, 1984.
15. **Pacini F**, Lari R, Taddei D, Grasso L, Martino E, Baschieri L and Pinchera A: Metastatic medullary and undifferentiated thyroid cancer are not associated with elevated levels of serum thyroglobulin. *Tumori* 70:417, 1984.
16. **Pacini F**, Vitti P, Martino E, Giani C, Bambini G, Pinchera A, Baschieri L: Treatment of refractory thyroid cancer with adriamycin. *Drugs Exptl Clin Res* 10:911, 1984.
17. **Pacini F**, Lari R, Grasso L, Taddei D, Biagini G, Gasperini L, Pinchera A: Radioimmunoassay of an iodinated fraction of thyroglobulin, 3,5,3',5' tetraiodo-l-tyrosil-l-tyrosine, in human serum. *J Lab Med* 12:379, 1985.
18. **Pacini F**, Martino E, Bambini G, Aghini-Lombardi F, Taddei D, Lari R, Baschieri L, Pinchera A: Humoral markers for thyroid carcinoma. *Cancer Detection and Prevention* 8:17, 1985.
19. **Pacini F**, Antonelli A, Lari R, Gasperini L, Baschieri L, Pinchera A: Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. *Ann Intern Med* 102:793, 1985.
20. **Pacini F**, Lari R, Mazzeo S, Grasso L, Taddei D and Pinchera A: Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. *Clin Endocrinol (Oxf)* 23:405, 1985.

21. Ambrosino N, **Pacini F**, Paggiaro PL, Martino E, Contini V, Turini L, Tarchi M, Vitti P, Bramanti M and Pinchera A: Impaired ventilatory drive in short-term primary hypothyroidism and its reversal by L-triiodothyronine. *J Endocrinol Invest* 8:533, 1985.
22. **Pacini F**, Elisei R, Anelli S, Gasperini L, Schipani E, and Pinchera A: Circulating neuron-specific enolase in medullary thyroid cancer. *Int J Biol Markers*, 2:85, 1986.
23. Fabris N, Mocchegiani E, Mariotti S, **Pacini F** and Pinchera A: Thyroid function modulated thymic endocrine activity. *J Clin Endocrinol Metab* 62:474, 1986.
24. Fabris N, Mocchegiani E, Mariotti S, Caramia G, Braccili T, **Pacini F**, Pinchera A. Thymulin deficiency and low 3,5,3'-Triiodothyronine syndrome in infants with low birth weight syndrome. *J Clin Endocrinol Metab* 65:247, 1987.
25. **Pacini F**, Perri G, Bagnolesi P, Cilotti A, Pinchera A. Mc Cune-Albright syndrome with gigantism and hyperprolactinemia. *J Endocrinol Invest* 10:417, 1987.
26. **Pacini F**, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. *J Nucl Med* 28:1888, 1987.
27. Ceccarelli C, **Pacini F**, Lippi F, Pinchera A. An unusual case of a false- positive iodine-131 whole body scan in a patients with papillary thyroid cancer. *Clin Nucl Med* 13:192, 1988.
28. **Pacini F**, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in thyrotoxic patients treated by surgery. *J Endocrinol Invest* 11:107, 1988.
29. **Pacini F**, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E, Pinchera A. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. *Acta Endocrinol (Copenh)* 119:373, 1988.
30. C. Ceccarelli, **F. Pacini**, F. Lippi, R. Elisei, M. Arganini, P. Miccoli, A. Pinchera. Thyroid cancer in children and adolescent. *Surgery* 104:1143, 1988.
31. **F. Pacini**, R. Elisei, S. Anelli, F. Basolo, A. Cola, A. Pinchera. Somatostatin in medullary thyroid cancer. In vivo and in vitro studies. *Cancer* 63:1189, 1989.
32. N. Fabris, E. Mocchegiani, S. Mariotti, **F. Pacini**, A. Pinchera. Thyroid-thymus interactions during development and aging. *Horm Res* 31:85, 1989.
33. C. Marcocci, **F. Pacini**, R. Elisei, E. Schipani, C. Ceccarelli, P. Miccoli, M. Arganini, A. Pinchera. Clinical and biological behaviour of bone metastases from differentiated thyroid carcinoma. *Surgery* 106:960, 1989.

34. **F. Pacini**, F. Basolo, R. Elisei, L. Fugazzola, A. Cola, A. Pinchera. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. *Am J Clin Pathol* 95:300-308, 1991.
35. **F. Pacini**, R. Elisei, L. Fugazzola, A. Pinchera. Humoral markers for thyroid carcinoma in clinical practice. *Diagn Oncol* 1:194-196, 1991.
36. **F. Pacini**, L. Fugazzola, F. Lippi, C. Ceccarelli, R. Centoni, P. Miccoli, R. Elisei, A. Pinchera. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic thyroid cancer. *J Clin Endocrinol Metab* 74:1401-4, 1992.
37. **F. Pacini**, L. Fugazzola, F. Basolo, R. Elisei, A. Pinchera. Expression of calcitonin gene-related peptide in medullary thyroid cancer. *J Endocrinol Invest* 15:539, 1992.
38. E. Martino, M.L. Murtas, A. Loviselli, M. Piga, L. Petrini, P. Miccoli, **F. Pacini**. Percutaneous intranodular ethanol injection for treatment of autonomously functioning thyroid nodules. *Surgery* 112:1161-5, 1992.
39. **F. Pacini**, L. Fugazzola, G. Bevilacqua, P. Viacava, V. Nardini, E. Martino. Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: Description of a new family. *J Endocrinol Invest* 16:295-6, 1993.
40. **F. Pacini**, R. Elisei, L. Fugazzola, C. Romei, A. Pinchera. Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer. *Acta Oncologica* 14:67-70, 1993.
41. L. Chiovato, G. Canale, D. Maccherini, V. Falcone, **F. Pacini**, A. Pinchera. Salmonella brandenburg: a novel cause of acute suppurative thyroiditis. *Acta Endocrinol* 128:439-42, 1993.
42. F. Basolo, L. Fugazzola, G. Fontanini, R. Elisei, S. Pepe, G. Bevilacqua, A. Pinchera, **F. Pacini**. Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. *Int. J. Oncol*, 3:1077-81, 1993.
43. I. Ceccherini, C. Romei, V. Barone, **F. Pacini**, E. Martino, A. Loviselli, A. Pinchera, G. Romeo. Identification of the Cys634-Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. *J Endocrinol Invest* 17:201-3, 1994.
44. **F. Pacini**, P. Miccoli, F. Cetani, S. Giardina, C. Ceccarelli, F. Lippi, P. Iacconi, E. Martino, A. Pinchera. Résultats du traitement par iode radioactif des métastases captantes des cancers différenciés de la thyroïde. *Lyon Chir* 90:19-21, 1994.
45. R. Elisei, A. Pinchera, C. Romei, M. Gryczynska, V. Pohl, C. Maenhaut, L. Fugazzola, **F. Pacini**. Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in

thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. *J Clin Endocrinol Metab* 78:867-71, 1994.

46. **F. Pacini**, M. Fontanelli, L. Fugazzola, R. Elisei, C. Romei, G. Di Coscio, P. Miccoli, A. Pinchera. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 78:826-29, 1994.
47. F. Basolo, A. Pinchera, L. Fugazzola, G. Fontanini, R. Elisei, C. Romei, **F. Pacini**. Expression of the p21 ras protein as a prognostic factor in papillary thyroid cancer. *Eur J Cancer* 30A:171-4, 1994.
48. L. Fugazzola, A. Pinchera, F. Luchetti, P. Iacconi, P. Miccoli, C. Romei, M. Puccini, **F. Pacini**. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid cancer. *Int J Biol Markers*, 9:21-4, 1994.
49. **F. Pacini**, A. Pinchera, F. Mancusi, L. Pollina, G. Fontanelli, G. Bevilacqua, F. Cartei, P. Miccoli, F. Basolo. Anaplastic thyroid carcinoma: a retrospective clinical and immunohistochemical study. *Oncol Rep* 1:921-5, 1994.
50. **F. Pacini**, M. Gasperi, L. Fugazzola, C. Ceccarelli, F. Lippi, R. Centoni, E. Martino, A. Pinchera. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. *J Nucl Med*, 35:1418-22, 1994.
51. **F. Pacini**, E. Martino, C. Romei, I. Ceccherini, F. Basolo, P. Iacconi, A. Pinchera. Treatment of preclinical medullary thyroid carcinoma in MEN 2A gene carrier. *Lancet*, 344:1084-5, 1994.
52. **F. Pacini**, F. Cetani, P. Miccoli, F. Mancusi, C. Ceccarelli, F. Lippi, E. Martino, A. Pinchera. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. *World J Surg* 18:600-4, 1994.
53. S. Mariotti, G. Barbesino, P. Caturegli, M. Marinò, L. Manetti, L. Fugazzola, **F. Pacini**, A. Pinchera. Serum soluble interleukin 2 (TL-2) receptor (sIL-2R) in differentiated thyroid carcinoma. *J Endocrinol Invest* 17:861-7, 1994.
54. S. Mariotti, G. Barbesino, P. Caturegli, M. Marinò, L. Manetti, **F. Pacini**, R. Centoni, A. Pinchera. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? *J Clin Endocrinol Metab* 80:468-72, 1995.
55. E. Martino, **F. Pacini**, P. Vitti, L. Bartalena. Percutaneous ethanol injection: what is its role in the management of nodular lesions of endocrine glands? *Eur J Endocrinol* 132:300-1, 1995.
56. **F. Pacini**, R. Elisei, L. Fugazzola, F. Cetani, C. Romei, F. Mancusi, A. Pinchera. Post-surgical follow-up of differentiated thyroid cancer. *J Endocrinol Invest* 18:165-6, 1995.

57. ED Williams, **F. Pacini**, A. Pinchera. Thyroid cancer following Chernobyl. *J Endocrinol Invest* 18:144-6, 1995.
58. **F. Pacini**, C. Romei, P. Miccoli, R. Elisei, E. Molinaro, F. Mancusi, P. Iacconi, F. Basolo, E. Martino, A. Pinchera. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for *ret* gene mutations. *Surgery* 118:1031-5, 1995.
59. L. Fugazzola, S. Pilotti, A. Pinchera, TV. Vorontsova, P. Mondellini, I. Bongarzone, A. Greco, L. Astakhova, MG. Butti, EP. Demidchik, **F. Pacini**, M.A. Pierotti. Oncogenic rearrangements of the *ret* proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. *Cancer Res* 55:5617-20, 1995.
60. C. Romei, R. Elisei, A. Pinchera, I. Ceccherini, E. Molinaro, F. Mancusi, E. Martino, G. Romeo, **F. Pacini**. Somatic mutations of the *ret* protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. *J Clin Endocrinol Metab* 81:1619-22, 1996.
61. L. Pollina, **F. Pacini**, G. Fontanini, S. Vignali, G. Bevilacqua, F. Basolo. *bcl-2*, *p53* and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. *Br J Cancer* 73:139-43, 1996.
62. G. Fontanini, S. Vignati, **F. Pacini**, L. Pollina, F. Basolo. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. *Mod Pathol* 9:636-41, 1996.
63. L. Fugazzola, M.A. Pierotti, E. Viganò, **F. Pacini**, T.V. Vorontsova, I. Bongarzone. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. *Oncogene* 13:1093-7, 1996.
64. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R. Gagel, H.K.P. von Amstel, C.J.M.Lips, I. Nishisho, S. Takai, D.J. Marsh, B.G.Robinson, K. Frank-Raue, F. Raue, F. Xue, W.W.Noll, C. Romei, **F. Pacini**, M. Fink, B. Niederle, J. Zedenius, M. Nordonskjold, P. Komminoth, G. Hendy, H. Gharib, S. N. Thibodeau, A. Lacroix, A. Frilling, B.A.J. Ponder, L. M. Mulligan. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. *JAMA* 276:1575-9, 1996.
65. C. Opasich, **F. Pacini**, N. Ambrosino, P.G. Riccardi, O. Febo, R. Ferrari, F. Cobelli, L. Tavazzi. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. *Eur Heart J*, 17:1860-66, 1996.
66. I. Bongarzone, L. Fugazzola, P. Vigneri, L. Mariani, P. Mondellini, **F. Pacini**, F. Basolo, A. Pinchera, S. Pilotti, M.A. Pierotti. Age-related activation of the tyrosine kinase receptor protooncogenes *ret* and *NTRK1* in papillary thyroid carcinoma. *J Clin Endocrinol Metab* 81:1713, 1996.

67. U. Feldt-Rasmussen, C. Profilis, E. Colinet, E. Black, H. Bornet, P. Bourdoux, P. Carayon, UB. Ericsson, DA. Koutras, L. Lamas de Leon, P. DeNayer, **F. Pacini**, G. Palumbo, A. Santos, M. Schlumberger, C. Seidel, AJ. Van Herle, JJM De Vijlder. Human thyroglobulin reference material (CRM 457). Ist part: Assesment of homogeneity, stability and immunoreactivity. *Ann Biol Clin (Paris)* 54:337-42, 1996.
68. U. Feldt-Rasmussen, C. Profilis, E. Colinet, E. Black, H. Bornet, P. Bourdoux, P. Carayon, UB. Ericsson, DA. Koutras, L. Lamas de Leon, P. DeNayer, **F. Pacini**, G. Palumbo, A. Santos, M. Schlumberger, C. Seidel, AJ. Van Herle, JJM De Vijlder. Human thyroglobulin reference material (CRM 457). 2nd part: Physicochemical characterization and certification. *Ann Biol Clin (Paris)* 54:343-48, 1996.
69. A. Pinchera, **F. Pacini**, T. Vorontsova, E. Demidchik, E. Molinaro. Radiation and thyroid cancer. *Eur. J Cancer Preven*, 5:386-8, 1996.
70. Basolo F, Pollina L, **Pacini F**, Fontanini G, Menard S, Castronovo V, Bevilacqua G. Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study. *Clin Cancer Res* 2:1777-80, 1996.
71. AM. Ferraris, R. Mangerini, GF. Gaetani, C. Romei, A. Pinchera, **F. Pacini**. Polyclonal origin of medullary thyroid carcinoma of the thyroid in multiple endocrine neoplasia type 2. *Hum Genet* 99:202-5, 1997.
72. F. Basolo, L. Pollina, G. Fontanini, L. Fiore, **F. Pacini**, A. Baldanzi. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. *Br J Cancer* 75:537-41, 1997.
73. Bongarzone I, Butti MG, Fugazzola L, **Pacini F**, Pinchera A, Vorontsova TV, Demidchik EP, Pierotti MA. Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. *Genomics* 42:252-9, 1997.
74. I. Ceccherini, B. Pasini, **F. Pacini**, M. Gallo, I. Bongarzone, C. Romei, G. Santamaria, I. Matera, P. Mondellini, L. Scopsi, A. Pinchera, M.A. Pierotti, G. Romeo. Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. *Oncogene* 14:2609-12, 1997.
75. M. Schlumberger, F. Mancusi, E. Baudin, **F. Pacini**. 131-I therapy for elevated thyroglobulin levels. *THYROID* 7:273-6, 1997.
76. **F. Pacini**, T. Vorontsova, EP. Demidchik, E. Molinaro, L. Agate, C. Romei, E. Shavrova, ED. Cherstvoy, Y. Ivashkevitch, E. Kuchinskaya, M. Schlumberger, G. Ronga, M. Filesi, A. Pinchera. Post-Chernobyl thyroid carcinoma in

Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. *J Clin Endocrinol Metab*, 82:3563-9, 1997.

77. L. Fiore, LE. Pollina, G. Fontanini, R. Casalone, MT. Berlingieri, R. Giannini, **F. Pacini**, P. Miccoli, A. Toniolo, A. Fusco, F. Basolo. Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. *J Clin Endocrinol Metab*, 82:4094-100, 1997.
78. **F. Pacini**, A. Vivaldi, M. Santoro, M. Fedele, A. Fusco, C. Romei, F. Basolo, A. Pinchera. Simian virus 40-like DNA sequences in human papillary thyroid carcinomas. *Oncogene*, 16:665-9, 1998.
79. **F. Pacini**, T. Vorontsova, E. Molinaro, E. Kuchinskaya, L. Agate, E. Shavrova, L. Astachova, L. Chiovato, A. Pinchera. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. *The Lancet*, 352:763-6, 1998.
80. Miccoli P, **Pacini F**, Basolo F, Iacconi P, Puccini M, Pinchera A. Thyroid carcinoma in a thyroglossal duct cyst: tumor resection alone or a total thyroidectomy? *Ann Chir*, 52:452-4, 1998.
81. **F. Pacini**, A. Pinchera. Serum and tissue thyroglobulin measurement: Clinical applications in thyroid disease. *Biochimie*, 81:463-7, 1999.
82. F. Cetani, M. Tonacchera, A. Pinchera, R. Barsacchi, F. Basolo, P. Miccoli, **F. Pacini**. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. *J Endocrinol Invest*, 22:273-8, 1999.
83. C. Ceccarelli, P. Battisti, M. Gasperi, E. Fantuzzi, **F. Pacini**, G. Gualdrini, MR. Pierantoni, A. Luciani, D. Djokich, A. Pinchera. Radiation dose to the testes after ¹³¹I therapy for ablation of post-surgical thyroid remnants in patients with differentiated thyroid cancer. *J Nucl Med* 40:1716-21, 1999.
84. BR. Haugen, **F. Pacini**, C. Reiners, M. Schlumberger, PW. Ladenson, SI. Sherman, DS. Cooper, KE. Graham, LE. Braverman, MC. Skarulis, TF. Davies, LJ. DeGroot, EL. Mazzaferri, GH. Daniels, DS. Ross, M. Luster, MH. Samuels, DV. Becker, HR. Maxon III, RR. Cavalieri, CA. Spencer, K. McEllin, BD. Weintraub, EC. Ridgway. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. *J Clin Endocrinol Metab* 84:3877-85, 1999.
85. **F. Pacini**. Thyroid Cancer (James A. Fagin Ed.). Book review. *N Engl J Med* 341:2023, 1999.
86. **Pacini F**, Vorontsova T, Molinaro E, Kuchinskaya E, Agate L, Sharova E, Astachova L, Chiovato L, Pinchera A. Radiation and thyroid autoimmunity. *Int J Radiat Med* 3-4:20-4, 1999.

87. Pinchera A, Molinaro E, Agate L, Elisei R, **Pacini F**. Treatment and follow-up protocol of radiation-induced thyroid cancer. *Int J Radiat Med (Uk)* 3-4:35-43, 1999.
88. **F. Pacini**, F. Lippi. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): Serum thyroglobulin measurement. *J Endocrinol Invest* 22 (Suppl.to N. 11):25-29, 1999.
89. MJ Schlumberger, C Incerti, **F Pacini**, C Reiners. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: A roundtable discussion. *J Endocrinol Invest* 22 (Suppl.to N. 11):35-41, 1999.
90. **F Pacini**, T Vorontsova, E Molinaro, E Shavrova, L Agate, E Kuchinskaya, R Elisei, EP Demidchik, A. Pinchera. Thyroid consequences of the Chernobyl nuclear accident. *Acta Paediatr (Suppl)* 433:23-7, 1999.
91. Gianini R, Salvatore G, Monaco C, Sferratore F, Pollina L, **Pacini F**, Basolo F, Santoro M. Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis. *Int J Oncol* 16:485-9, 2000.
92. Elisei R, Romei C, Soldatenko PP, Cosci B, Vorontsova T, Vivaldi A, Basolo F, Cherstvoy ED, Pinchera A, **Pacini F**. New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. *Clin Endocrinol (Oxf)* 53:131-6, 2000.
93. F. Basolo, F. Pisaturo, L.E. Pollina, G. Fontanini, R. Elisei, E. Molinaro, P. Iaconi, P. Miccoli, **F. Pacini**. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. *Thyroid* 10:19-23, 2000.
94. F Basolo, MA Caligo, A Pinchera, F Fedeli, A Baldanzi, P Miccoli, P Iaconi, G Fontanini, **F Pacini**. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. *Thyroid* 10:741-6, 2000.
95. F Basolo, L Fiore, A Baldanzi, R Giannini, M Dell'Omodarme, G Fontanini, **F Pacini**, R Danesi, P Miccoli, A Toniolo. Suppression of Fas expression and down-regulation of Fas ligand in highly aggressive human thyroid carcinoma. *Lab Invest* 80:1413-9, 2000.
96. Lippi F, Capezzone M, Miccoli P, Traino C, Di Martino F, Angelini F, Spinelli C, Iaconi P, Pinchera A, **Pacini F**. Use of surgical gamma probe for the detection of lymph node metastases in differentiated thyroid cancer. *Tumori* 86:367-9, 2000.
97. **Pacini F**, Elisei R, Romei C, Pinchera A. RET proto-oncogene mutations in thyroid carcinoma: clinical relevance. *J Endocrinol Invest* 23:328-38, 2000.

98. Schlumberger M, Ricard M, **Pacini F**. Clinical use of recombinant human TSH in thyroid cancer patients. *Eur J Endocrinol* 143:557-63, 2000.
99. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, **Pacini F**. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. *Eur J Endocrinol* 144:5-11, 2001.
100. Oliynyk V, Epshtein O, Sovenko T, Tronko M, Elisei R, **Pacini F**, Pinchera A. Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. *J Endocrinol Invest* 24:445-7, 2001.
101. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A, **Pacini F**. Ret/ptc rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. *J Clin Endocrinol Metab* 86:3211-6, 2001.
102. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, **Pacini F**. ¹³¹I-Therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. *J Clin Endocrinol Metab* 86:3512-5, 2001.
103. **Pacini F**, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic ¹³¹I whole body scan: comparison of patients treated with high ¹³¹I activities versus untreated patients. *J Clin Endocrinol Metab* 86:4092-7, 2001.
104. **Pacini F**, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F, Agate L, Bottici V, Raffaelli M, Pinchera A. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. *Thyroid* 11:877-81, 2001.
105. **Pacini F**, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 86:5686-90, 2001.
106. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJM, Lombardi G, Mammelli M, **Pacini F**, Ponder BAJ, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SAJr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 86:5658-71, 2001.
107. Basolo F, Molinaro E, Agate L, Pinchera A, Pollina L, Chiappetta G, Monaco C, Santoro M, Fusco A, Miccolo P, Elisei R, Capezzone M, **Pacini F**. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. *Eur J Endocrinol* 145:599-604, 2001.

108. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, **Pacini F**, Elisai R, Miccoli P, Pinchera A, Fusco A, Santoro M. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. *Am J Pathol* 160:247-54, 2002.
109. Basolo F, Giannini R, Toniolo A, Casalone R, Nikiforova M, **Pacini F**, Elisei R, Miccoli P, Berti P, Faviana P, Fiore L, Monaco C, Pierantoni GM, Fedele M, Nikiforov YE, Santoro M, Fusco A. Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. *Int J Cancer*. 97:608-14, 2002.
110. **Pacini F**, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-Iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. *J Clin Endocrinol Metab* 87:1499-1501, 2002.
111. Spinelli C, Puccini M, Bertocchini A, Lima M, **Pacini F**, Miccoli P. Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET protooncogene. *Pediatr Med Chir*. 24:53-7, 2002.
112. **Pacini F**. Thyroid cancer in children and adolescents. *J Endocrinol Invest* 25:572-3, 2002.
113. **Pacini F**. Follow-up of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 29 (Suppl 2) 492-6, 2002.
114. **Pacini F**, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A. Ablation of thyroid residues with 30 mCi (¹³¹I): a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. *J Clin Endocrinol Metab*. 87:4063-8, 2002.
115. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, **Pacini F**. Cytotoxic effects of carboplatin and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. *J Clin Endocrinol Metab*. 87:4160-5, 2002.
116. Miccoli P, Elisei R, Materazzi G, Capezzone M, Galleri, D, **Pacini F**, Berti P, Pinchera A. Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness. *Surgery* 132:1070-4, 2002.
117. **Pacini F**. Role of percutaneous ethanol injection in management of nodular lesions of the thyroid gland. *J Nucl Med* 44:211-2, 2003.
118. Vivaldi A, **Pacini F**, Martini F, Iaccheri L, Pezzetti F, Elisei R, Pinchera A, Faviana P, Basolo F, Tognon M. Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. *J Clin Endocrinol Metab*. 88:892-9, 2003.

119. E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, **F. Pacini**, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, S. Lee, T. F. Davies, B. M. Arafah, P. W. Ladenson and A. Pinchera. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab.* 88:1433-41, 2003.
120. **Pacini F**, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 88:3668-73, 2003.
121. J Lado-Abeal, E Molinaro, E De Valk, **F Pacini**, S Refetoff. The Effect of Short-Term Treatment with Recombinant Human Thyroid-Stimulating Hormones on Leydig Cell Function in Men. *Thyroid*, 13: 649-652, 2003.
122. Chiovato L, Latrofa F, Braverman LE, **Pacini F**, Capezzone M, Masserini L, Grasso L, Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. *Ann Intern Med* 139:346-51, 2003.
123. Giannini R, Faviana P, Cavinato T, Elisei R, **Pacini F**, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A, Basolo F. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. *Thyroid* 13:765-70, 2003.
124. Elisei R, Vivaldi A, **Pacini F**. Biology and clinical application of the NIS gene. *Tumori* 89:523-8, 2003.
125. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L, Pinchera A, **Pacini F**. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. *J Clin Endocrinol Metab* 89:33-9, 2004.
126. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, basolo F, Pinchera A, **Pacini F**. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. *J Clin Endocrinol Metab* 89:163-8, 2004.
127. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Lambert E, Lind P, **Pacini F**, Reiners C, Franco FS, Toft A, Wiersinga WM. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. *Eur J Endocrinol* 150:105-112, 2004.
128. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribachi R, Falorni A, Pontecorvi A, **Pacini F**, Pinchera A, Santeusano F. BRAF^{V599E} Mutation is the leading

event in sporadic papillary thyroid carcinomas. *J Clin Endocrinol Metab* 89:2414-20, 2004.

129. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, **Pacini F**, Pinchera A. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. *J Clin Endocrinol Metab* 89:3579-84, 2004.
130. **Pacini F**, Burrioni L, Ciuoli C, Di Cairano G, Guarino E. Management of thyroid nodules: a clinicopathological, evidence-based approach. *Eur J Nucl Med Mol Imaging* 31:1443-9, 2004.
131. Schlumberger M, **Pacini F**, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Lambert E, Jarzab B, Jamar F, Duntas L, Cohen G. Follow-up and management of differentiated thyroid carcinoma: European perspective in clinical practice. *Eur J Endocrinol* 151:539-48, 2004.
132. Biscolla RP, Ugolini C, Sculli M, Bottici V, Castagna MG, Romei C, Cosci B, Molinaro E, Faviana P, Basolo F, Miccoli P, **Pacini F**, Pinchera A, Elisei R. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. *Thyroid* 14:946-52, 2004.
133. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampiani P, Romei C, Faviana P, Basolo F, Miccoli P, Capodanno A, Collecchi P, **Pacini F**, Pinchera A. All-trans retinoic acid treatment inhibits the growth of RAR β mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes. *J Clin Endocrinol Metab*. 90:2403-11, 2005.
134. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners Christoph, **Pacini F**. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. *Endocrine-Related Cancer* 12:149-64, 2005.
135. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, **Pacini F**, Santini F, Elisei R. Influence of human body composition on serum peak TSH after rhTSH administration in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab*. 90:4047-50, 2005.
136. Guarino E, Tarantini B, Pilli T, Checchi S, Brillì L, Ciuoli C, Di Cairano G, Mazzucato P, **Pacini F**. Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. *THYROID* 15:1041-45, 2005.
137. **Pacini F**, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Lambert E, Lind P, Reiners C, Franco FS, Smit J, Wiersinga W. Post-surgical use of radioiodine (¹³¹I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. *Eur J Endocrinol*. 153:651-9, 2005.

138. Elisei R, Romei C, Castagna MG, Lisi S, Vivaldi A, Faviana P, Marino M, Ceccarelli C, **Pacini F**, Pinchera A. RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin Concentration. *Thyroid*. 15:1355-61, 2005.
139. Checchi S, Brilli L, Guarino E, Ciuoli C, Di Cairano G, Mazzucato P, **Pacini F**. Cyclic Cushing's disease with paradoxical response to dexamethasone. *J Endocrinol Invest*. 28:741-5, 2005.
140. **Pacini F**, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. *J Clin Endocrinol Metab* 91:926-932, 2006.
141. Schroeder PR, Haugen BR, **Pacini F**, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A Comparison of Short-term Changes in Health-related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with rhTSH Compared to Thyroid Hormone Withdrawal. *J Clin Endocrinol Metab*. 91:878-884, 2006.
142. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, Traino C, **Pacini F**, Pinchera A. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter (nis) cDNA. *J Clin Endocrinol Metab*. 91:2389-95, 2006.
143. **Pacini F**, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol*, 154:1-18, 2006.
144. **Pacini F**. Why do we need guidelines for differentiated thyroid cancer? *THYROID* 16:103-4, 2006.
145. Hanscheid H, Lassmann M, Luster M, Thomas SR, **Pacini F**, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal. *J Nucl Med*. 47:648-654, 2006.
146. Antunes TT, Gagnon A, Chen B, **Pacini F**, Smith TJ, Sorisky A. Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-

stimulating hormone: effect of adipocyte differentiation and anatomic depot. *Am J Physiol Endocrinol Metab.* 290:E1140-4, 2006.

147. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, **Pacini F**, Pinchera A, Santeusanio F, Elisei R. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. *Endocr Related Cancer* 13:455-64, 2006.
148. Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, Burrioni L, Vattimo AG, **Pacini F**. Effectiveness of radioiodine (¹³¹I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. *J Endocrinol Invest* 29:594-8, 2006.
149. Schlumberger M, Borget I, De Pouvourville G, **Pacini F**. Recombinant human thyroid-stimulating hormone : use in papillary and follicular thyroid cancer. *Horm Res* 67 (Suppl 1):132-42, 2007.
150. **Pacini F**, Castagna MG, Brilli L, Pilli T. Application of recombinant human TSH in the diagnosis and treatment of thyroid diseases. *HOT THYROIDOLOGY* (www.hotthyroidology.com), March, No 2, 2007.
151. Tania Pilli, Ernesto Brianzoni, Francesca Capocchetti, Maria Grazia Castagna, Sara Fattori, Angela Poggiu, Gloria Rossi, Francesca Ferretti, Elisa Guarino, Luca Burrioni, Angelo Vattimo, Claudia Cipri, and **Furio Pacini**. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) ¹³¹iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. *J Clin Endocrinol Metab* 92:3542-46, 2007.
152. Checchi S, Montanaro A, Pasqui L, Ciuoli C, Cevenini G, Sestini F, Fioravanti C, **Pacini F**. Serum Ghrelin As a Marker of Atrophic Body Gastritis in Patients With Parietal Cell Antibodies. *J Clin Endocrinol Metab* 92:4346-51, 2007.
153. Schlumberger M, Ricard M, De Pouvourville G, **Pacini F**. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. *Nat Clin Pract Endocrinol Metab*, 3:641-50, 2007.
154. Brilli L, Guarino E, Ghezzi M, Carli AF, Occhini R, **Pacini F**. Multinodular goiter of unusual shape and location. *Thyroid*.17:693-4, 2007.
155. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, **Pacini F**, Pinchera A. Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center. *J Clin Endocrinol Metab.* 92:4725-9, 2007.

156. Pazaitou-Panayiotou K, Capezzone M, **Pacini F**. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. *Thyroid*.17:1085-92, 2007.
157. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, **Pacini F**. Limited Value of Repeat Recombinant Thyrotropin (rhTSH)-Stimulated Thyroglobulin Testing in Differentiated Thyroid Carcinoma Patients With Previous Negative rhTSH-Stimulated Thyroglobulin and Undetectable Basal Serum Thyroglobulin Levels. *J Clin Endocrinol Metab*. 93:76-81, 2008.
158. Checchi S, Montanaro A, Pasqui L, Ciuoli C, De Palo V, Chiappetta MC, **Pacini F**. l-thyroxine (l-T4) requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. *J Clin Endocrinol Metab*. 93:465-9, 2008.
159. Ferrari FS, Megliola A, Scorzelli A, Guarino E, **Pacini F**. Ultrasound examination using contrast agent and elastosonography in the evaluation of single thyroid nodules: preliminary results. *Journal of Ultrasound* 11:47-54, 2008.
160. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, **Pacini F**, Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study. *J Clin Endocrinol Metab*. 93:682-7, 2008.
161. **Pacini F**. Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer?-Utility of RECIST Criteria. *Thyroid*. 18:279-80, 2008.
162. Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, Valleggi F, Campagna S, Franci B, Avanzati A, Nuti R, **Pacini F**. The Effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. *Thyroid*. 18:455-60, 2008.
163. Agate L, Mariotti S, Elisei R, Mossa P, **Pacini F**, Molinaro E, Grasso L, Masserini L, Mokhort T, Vorontsova T, Arynchyn A, Tronko MD, Tsyb A, Feldt-Rasmussen U, Juul A, Pinchera A. Thyroid autoantibodies (ATA) and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. *J Clin Endocrinol Metab*. 93:2729-36, 2008.
164. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, **Pacini F**, Pinchera A, Elisei R. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. *Endocr Relat Cancer*. 15:511-520, 2008.

165. **Pacini F**, Castagna MG, Brilli L, Jost L; ESMO Guidelines Working Group. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 19 Suppl 2:99-101, 2008.
166. Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, **Pacini F**. Expanding Indications for Recombinant Human TSH in Thyroid Cancer. *Thyroid*. 2008;18:687-94.
167. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group: Lind P, Pirich C, Daumerie C, Baudin E, Bui BN, Conte-Devolx B, Rohmer V, Schwartz C, Szabolcs I, Racz K, Brandi ML, Pinchera A, Elisei R, Orlandi F, **Pacini F**, Jarzab B, Sowinski J, Jansson S, Lundell G, Hallqvist A, Meier C, Philippe J, Agarwala S, Ali H, Barrera J, Boccia R, Bukowski R, Burman K, Clark O, Davis T, Hoff A, Sarlis N, Jakub J, Mena R, Nahleh Z, Rosen L, Stephenson J, Srkalovic G, Tchekmedyan N. Motesanib diphosphate in progressive differentiated thyroid cancer. *N Engl J Med*. 359:31-42, 2008.
168. Marco Capezzone, Silvia Cantara, Stefania Marchisotta, Sebastiano Filetti, Maria Margherita De Santi, Benedetta Rossi, Giuseppe Ronga, Cosimo Durante, **Furio Pacini**. Short telomeres, hTERT gene amplification and increased telomerase activity in the blood of familial papillary thyroid cancer patients. *J Clin Endocrinol Metab* 93:3950-7, 2008.
169. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, Carli A, Caruso G, Toti P, Capitani S, Pammolli A, **Pacini F**. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. *Endocr Relat Cancer* 15:1075-81, 2008.
170. **F Pacini**, MG Castagna. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. *Best Pract Res Clin Endocrinol Metab*. 22:1009-1021, 2008.
171. **Pacini F**. Best practice & Research Clinical Endocrinology & Metabolism. Thyroid nodules and cancer. Preface. *Best Pract Res Clin Endocrinol Metab*. 22:vii, 2008.
172. Luster M, Schlumberger M, **Pacini F**. Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. *Eur J Nucl Med Mol Imaging*. 36:329-30, 2009.
173. Subramanian M, Pilli T, Bhattacharya P, **Pacini F**, Nikiforov YE, Kanteti PV, Prabhakar BS. Knockdown of IG20 Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis. *J Clin Endocrinol Metab*. 94:1467-71, 2009.

174. Cerase A, Venturi C, Rubenni E, Tarantini B, **Pacini F**. Complete Regression of a Temporal Stem Dilated Perivascular Space Following Resection of a Pituitary Nonfunctioning Macroadenoma. *AJNR Am J Neuroradiol.* 30:E4-5, 2009.
175. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, **Pacini F**, Ringel MD, Schlumberger M, Wells SA. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. *Thyroid.* 19:565-612, 2009
176. **Pacini F**, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol.* 20 Suppl 4:143-6, 2009.
177. Tarantini B, Ciuoli C, Checchi S, Montanaro A, Bonato V, Theodoropoulou A, Pasqui L, **Pacini F**. Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine test. *J Endocrinol Invest.* 32:335-7, 2009.
178. Schlumberger MJ, **Pacini F**. The low utility of pretherapy scans in thyroid cancer patients. *Thyroid.* 19:815-6, 2009.
179. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, **Pacini F**, Cho SY, Magner J, Pinchera A, Ladenson PW Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. *J Clin Endocrinol Metab.* 94:4171-9, 2009.
180. M. Capezzone, S. Marchisotta, S. Cantara and **F. Pacini**. Telomeres and Thyroid Cancer. *Current Genomics,* 10:526-33, 2009.
181. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, **Pacini F**, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid,* 19:1167-214, 2009.
182. **Pacini F**, Brilli L, Marchisotta S. Targeted therapy in radioiodine refractory thyroid cancer. *Q J Nucl Med Mol Imaging.*53:520-5, 2009.
183. Subramanian M, Pilli T, Prasad KV, Jayarama S, **Pacini F**, Prabhakar BS. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. *Thyroid.* 19:1333-42, 2009.
184. Bombardieri E, **Pacini F**. Radioiodine therapy a successful tool in treating thyroid cancer. Foreword. *Q J Nucl Med Mol Imaging.* 53:439, 2009.

185. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, **Pacini F**, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. *J Clin Oncol.* 27:3794-801, 2009.
186. Marchisotta S, **Pacini F**. Diagnosis of medullary thyroid cancer. *F1000 Med Rep.* 2009 Mar 17;1. pii: 19.
187. Hernan P. Tala Jury, Maria Grazia Castagna, Carla Fioravanti, Claudia Cipri, Ernesto Brianzoni, and **Furio Pacini**. Lack of Association between Urinary Iodine Excretion and Successful Thyroid Ablation in Thyroid Cancer Patients. *J Clin Endocrinol Metab.* 95:230-7, 2010.
188. Silvia Cantara, Marco Capezzone, Stefania Marchisotta, Serena Capuano, Giulia Busonero, Paolo Toti, Andrea Di Santo, Giuseppe Caruso, Anton Ferdinando Carli, Lucia Brillì, Annalisa Montanaro, and **Furio Pacini**. Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. *J Clin Endocrinol Metab.* 95:1365-69, 2010.
189. Rossella Elisei, Eleonora Molinaro, Laura Agate, Valeria Bottici, Lucio Masserini, Claudia Ceccarelli, Francesco Lippi, Lucia Grasso, Fulvio Basolo, Generoso Bevilacqua, Paolo Miccoli, Giancarlo Di Coscio, Paolo Vitti, **Furio Pacini**, and Aldo Pinchera. Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. *J Clin Endocrinol Metab.* 95:1516-27, 2010.
190. Santini F, Galli G, Maffei M, Fierabracci P, Pelosini C, Marsili A, Giannetti M, Castagna M, Checchi S, Molinaro E, Piaggi P, **Pacini F**, Elisei R, Vitti P, Pinchera A. Acute exogenous TSH administration stimulates leptin secretion in vivo. *Eur J Endocrinol.* 163:63-7, 2010.
191. Romei C, Mariotti S, Fugazzola L, Taccaliti A, **Pacini F**, Opocher G, Mian C, Castellano M, Ceccherini I, Degli Uberti E, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Uberta V, Boscaro M, Casatagna M, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R. Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *Eur J Endocrinol.* 163:301-8, 2010.
192. **Pacini F**, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. *Clin Oncol (R Coll Radiol).* 22:475-85, 2010.

193. **Pacini F**, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 21 Suppl 5:v214-9, 2010.
194. Cantara S, Capuano S, Formichi C, Pisu M, Capezzone M, **Pacini F**. Lack of germline A339V mutation in thyroid transcription factor-1 (TTF-1/NKX2.1) gene in familial papillary thyroid cancer. *Thyroid Res*. 3:4, 2010.
195. **F. Pacini**, S. Cantara, M. Capezzone. Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth ? *J Endocrinol Invest* 33:576-8, 2010.
196. S Checchi, A Montanaro, C Ciuoli, L Brusco, L Pasqui, C Fioravanti, F Sestini, **F Pacini**. Prevalence of Parietal Cell Antibodies in a Large Cohort of Patients with Autoimmune Thyroiditis. *Thyroid*. 20: 1385-1389, 2010.
197. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, **Pacini F**. The use of ultrasensitive thyroglobulin assays reduces but not abolishes the need for TSH stimulation in patients with differentiated thyroid carcinoma. *J Endocrinol Invest*. 2011 Mar 7. [Epub ahead of print].
198. H. Graf, S. Fast, F. **Pacini**, A. Pinchera, A. Leung, M. Vaisman, C. Reiners, J. Wemeau, D. Huysmans, W. Harper, A. Driedger, H. Noemberg de Souza, M.G. Castagna, L. Antonangeli, L. Braverman, R. Corbo, C. Duren, E. Proust-Lemoine, M.A. Edelbroek, C. Marriott, I. Rachinsky, T. Watt, J. Magner, L. Hegedus. Modified-release recombinant human TSH (MRrhTSH) augments the effect of ¹³¹I therapy in benign multinodular goiter: Results from a multicenter international, randomized, placebo-controlled study. *J Clin Endocrinol Metab* 96:000-0, 2011. Ahead of print Feb. 23, 2011 doi:10.1210/jc.2010-1193.
199. **Furio Pacini**, Silvia Cantara, Marco Capezzone & Stefania Marchisotta. Telomerase and the endocrine system. *Nat Rev Endocrinol*, 7:420-30, 2011.
200. **Pacini F**. Management of differentiated thyroid cancer of the follicular epithelium. *Ann Med*. 2011 Jun 13. [Epub ahead of print]
201. Brilli L, **Pacini F**. Targeted therapy in refractory thyroid cancer: current achievements and limitations. *Future Oncol*. 7:657-68, 2011.
202. **Pacini F**, Sabra MM, Tuttle RM. Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. *Thyroid*. 21:691-2, 2011.
203. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, **Pacini F**. Delayed Risk Stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *Eur J Endocrinol*. 165:441-6, 2011.

204. Capezzone M, Cantara S, Marchisotta S, Busonero G, Formichi C, Benigni M, Capuano S, Toti P, Pazaitou-Panayiotou K, Caruso G, Carli AF, Palummo N, **Pacini F**. Telomere Length in Neoplastic and Nonneoplastic Tissues of Patients with Familial and Sporadic Papillary Thyroid Cancer. *J Clin Endocrinol Metab.* 96:E1852-6, 2011.
205. Cristina Ciuoli, Lucia Brusco, Alexandra Theodoropoulou, Maria Grazia Castagna, Ornella Neri, Letizia Pasqui and **Furio Pacini**. Effects of acute recombinant human TSH on serum ghrelin levels. doi: 10.3389/fendo.2011.00094. *Frontiers in Endocrinology* 2:94, 2011.
206. **Pacini F**. Screening of Thyroid Nodules by Serum Calcitonin Measurements: Why Not? *Thyroid.* 22:103, 2012.
207. Cantara S, Capuano S, Capezzone M, Benigni M, Pisu M, Marchisotta S, **Pacini F**. Lack of Mutations of the Telomerase RNA Component in Familial Papillary Thyroid Cancer with Short Telomeres. *Thyroid.* 22:363-8, 2012.
208. **Furio Pacini**, Maria Grazia Castagna. Approach to and Treatment of Differentiated Thyroid Carcinoma. *Med Clin N Am* 96:369–383, 2012.
209. Cantara S, Pisu M, Frau DV, Caria P, Dettori T, Capezzone M, Capuano S, Vanni R, **Pacini F**. Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. *J Clin Endocrinol Metab.* 97:E1327-31, 2012.
210. **Pacini F**. Thyroid microcarcinoma. *Best Pract Res Clin Endocrinol Metab.* 26:421-9, 2012.
211. **Pacini F**. Thyroid Function: Optimizing molecular testing in thyroid nodule cytology. *Nat Rev Endocrinol.* 8:390-1, 2012.
212. **Pacini F**. Changing natural history of differentiated thyroid cancer. *Endocrine.* *Endocrine* 42:229–230, 2012.
213. Silvia Cantara, Francesco D'Angeli, Paolo Toti, Luca Lignitto, Maria Grazia Castagna, Serena Capuano, Bellur S. Prabhakar, Antonio Feliciello, **Furio Pacini**. Expression of the Ring Ligase PRAJA2 in Thyroid Cancer. *J Clin Endocrinol Metab.* 2012 Sep 4. Epub ahead of print.
214. **F. Pacini**, M.G. Castagna, L. Brillì, G. Penteroudakis, on behalf of the ESMO Guidelines Working Group. Thyroid Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23 (Suppl. 7):vii110-vii119, 2012.
215. Schlumberger M BL, Dralle H, Jarzab B, **Pacini F**, Smit JWA and the European Task Force. 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. *European Thyroid Journal.* 1:5-14, 2012.

216. **Pacini F**, Castagna MG. New insight in the follow-up strategies of differentiated thyroid cancer. *J Endocrinol Invest.* 35 (Suppl 6):36-9, 2012.
217. **Furio Pacini**, Yasuhiro Ito, Markus Luster, Fabian Pitoia, Bruce Robinson and Lori Wirth. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. *Expert Rev. Endocrinol. Metab.* 7:541–554, 2012.
218. Li L, Jayarama S, Pilli T, Qian L, **Pacini F**, Prabhakar BS Phd. Down modulation of IG20/MADD expression or phosphorylation renders TRAIL resistant thyroid cancer cells susceptible to TRAIL treatment. *Thyroid.* 23:70-8, 2013.
219. **Furio Pacini**. Management of papillary thyroid microcarcinoma: Primum non nocere! *J Clin Endocrinol Metab* 98:1391-3, 2013.
220. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Cipri C, Belardini V, Brianzoni E, **Pacini F**. POST-SURGICAL THYROID ABLATION WITH LOW OR HIGH RADIOIODINE ACTIVITIES RESULTS IN SIMILAR OUTCOMES IN INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER PATIENTS. *Eur J Endocrinol.* 2013 Apr 17. [Epub ahead of print].